arrow
C

Craig M. McDonald

university of california davis
H指数:75
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial

德尔帕西bart佐塔迪森在美国杜氏肌营养不良症中可经外显子44跳跃突变的疗效与安全性(EXPLORE44):一项随机、安慰剂对照、双盲、1/2期临床试验

2026-10-140
PRE
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

Deramiocel心脏源性细胞疗法治疗晚期杜氏肌营养不良症 (HOPE-3): 一项3期随机、双盲、安慰剂对照试验

2026-07-290
OAAI
Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up

达兰迪斯特罗金(Delandistrogene Moxeparvovec)治疗杜氏肌营养不良症临床试验中的心脏安全性结局,随访时间长达5年

2026-07-010
OAAI
Heart Transplantation and Ventricular Assist Device in Duchenne Muscular Dystrophy: A New Era

心脏移植与心室辅助装置在杜氏肌营养不良症中的应用:一个新时代

2025-12-210
PRE
Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4-to <7-year children

vamorolone(一种解离性皮质类固醇抗炎药)对4至<7岁儿童血清生物标志物的暴露-反应关系

2025-11-010
OAAI
Descriptive characterization of ambulatory health states in Duchenne muscular dystrophy: Motor function trajectories and times to loss of ambulation

杜氏肌营养不良症中非卧床健康状态的描述性特征:运动功能轨迹及丧失行走能力的时间

2025-09-230
OA
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy

关于在杜氏肌营养不良症患者中实施基因治疗及监测的共识推荐与考量

2025-08-230
PRE
Long-Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons

吉温司他(Givinostat)在杜氏肌营养不良症中的长期评估及自然病史比较

2025-08-190
OA
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial

AAV基因治疗杜氏肌营养不良症: EMBARK 3期随机试验

2024-10-093
OAAI
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy

Vamorolone在Duchenne肌营养不良症男孩中48周的疗效和安全性

2024-03-1211
OAAI
Findings from the Longitudinal CINRG Becker Natural History Study
2023-11-175
OAAI
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged=4 to <8?Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)
2023-09-0736
OA
Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
2023-04-253
PRE